Calcineurin inhibitors, like Cyclosporin and Tacrolimus, target T-cells.
Epratuzumab targets B-cells.
Sifalimumab targets interferon-α of the innate immune response. It is anticipated to be the next big thing in Lupus treatment.
Rituximab must be the most widely used drug for Lupus that has failed all clinical trials in Lupus. In fact, it is the go-to drug in SLE when all else fails (short of ablative chemotherapy with haemopoietic stem cell rescue).
Obviously, 100% of rheumatologists can't be wrong. We blame trial design for the trial failure, obviously. Our esteemed clinical acumen trumps evidence-based medicine, anytime.
This is not said tongue-in-cheek: 100% of rheumatologists believe so. Is it any wonder then that 99% of treatment in Rheumatology is "off-label"?